{"contentid": 487969, "importid": NaN, "name": "Korsuva accepted for FDA priority review in pruritis", "introduction": "Swiss drugmaker Vifor Pharma and Cara Therapeutics today announced that the US Food and Drug Administration has accepted and granted Priority Review for the New Drug Application (NDA) for Korsuva (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients.", "content": "<p>Swiss drugmaker Vifor Pharma (VTX: VIFN) and Cara Therapeutics (Nasdaq: CARA) today announced that the US Food and Drug Administration has accepted and granted Priority Review for the New Drug Application (NDA) for Korsuva (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients.</p>\n<p>The Prescription Drug User Fee Act (PDUFA) target action date for Korsuva is August 23, 2021. The FDA stated that currently it is not planning to hold an advisory committee meeting to discuss the application.</p>\n<p>Vifor and Cara entered into a <a href=\"https://www.thepharmaletter.com/article/korsuva-commercialization-plans-lined-up-in-the-usa\">collaboration on Korsuva</a> in October 2020, under which the US firm receive an upfront payment of $100 million in cash and an equity investment of $50 million and eligibility for a total of $290 million. Vifor&rsquo;s shares were up 3.8% at 121.35 Swiss francs by mid-morning.</p>\n<p>The NDA filing is supported by positive data from two pivotal phase-III trials KALM-1, conducted in the USA (<a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa1912770\">New England Journal of Medicine 2020; 382:222-232</a>) and the global KALM-2, as well as supportive data from an additional 32 clinical studies.</p>\n<h2><strong>Pruritis impacts up to 40% of dialysis patients</strong></h2>\n<p>&ldquo;We are delighted that the FDA accepted and granted Priority Review for this breakthrough therapy. Pruritus in hemodialysis patients is a debilitating condition with a significant impact on quality of life and increased risk for hospitalization and mortality. It impacts up to 40% of dialysis patients around the world. If Korsuva is approved, we will be able to offer a medicine that is in line with our aim to deliver innovative therapies to patients with high unmet medical needs. We are highly committed to bringing this important new treatment to patients in the US as soon as possible following FDA approval, together with our partner Cara Therapeutics,&rdquo; commented Stefan Schulze, chief executive of Vifor Pharma Group.</p>\n<p>&ldquo;The FDA acceptance for filing and granting of Priority Review for the Korsuva NDA marks a significant milestone for Cara and for the substantial number of hemodialysis patients&nbsp;with chronic intractable pruritus,&rdquo; said Derek Chalmers, president and CEO of Cara Therapeutics. &ldquo;FDA&rsquo;s agreement to expedite the timeline through Priority Review designation aligns with our understanding of the therapeutic potential of Korsuva to fundamentally change the treatment paradigm for this serious unmet need. We look forward to working with the FDA through the review process and, along with our commercial partner, Vifor Pharma, remain focused on preparing for the US launch of Korsuva injection, if approved.&rdquo;</p>", "date": "2021-03-08 10:19:00", "meta_title": "Korsuva accepted for FDA priority review in pruritis", "meta_keywords": "Vifor Pharma. Cara Therapeutics, Korsuva, Pruritis, Hemodialysis patients, Priority review, NDA, Accepted", "meta_description": "Korsuva accepted for FDA priority review in pruritis", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-08 10:16:54", "updated": "2021-03-08 10:28:57", "access": NaN, "url": "https://www.thepharmaletter.com/article/korsuva-accepted-for-fda-priority-review-in-pruritis", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "vifor-big.jpg", "image2id": "vifor-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Hemodialysis", "sector_tag": "Pharmaceutical", "therapy area_tag": "Nephrology and Hepatology", "topic_tag": "Focus On, One to Watch Companies, Regulation, US FDA", "geography_tag": "Switzerland, USA", "company_tag": "Cara Therapeutics, Vifor Pharma", "drug_tag": "Korsuva, Priority Review", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-08 10:19:00"}